In a nutshell This study investigated the effectiveness of erlotinib (Tarceva) and bevacizumab (Avastin) compared ti erlotinib alone in non-small cell lung cancer (NSCLC). They found that combined treatment improved survival after 12 months. Some background Non-small cell lung cancer (NSCLC) is a common type of lung cancer (LC)....
Read MoreType of lung cancer-Non-small cell lung carcinoma (NSCLC) Posts on Medivizor
Chemotherapy and radiotherapy alongside treatment with cetuximab for non-small cell lung cancer
In a nutshell This study evaluated the effectiveness of adding cetuximab (Erbitux) to standard chemotherapy and radiotherapy treatment for advanced non-small cell lung cancer (NSCLC). This study found that adding cetuximab to chemotherapy and radiotherapy resulted in promising outcomes. Some background NSCLC is the...
Read MoreEvaluating crizotinib for patients with non-small cell lung cancer that has spread to the brain
In a nutshell This study evaluated how well crizotinib (Xalkori) works in patients with non-small cell lung cancer (NSCLC) with an ALK mutation that had spread to the brain. This study found that crizotinib treatment improved survival, but not for patients with cancer in the brain that continued to grow. Some background NSCLC is the most common type...
Read MoreIs crizotinib an effective treatment for advanced non-small cell lung cancer?
In a nutshell This study investigated the safety and effectiveness of crizotinib (Xalkori) in advanced non-small cell lung cancer (NSCLC). They found that this treatment improved survival in advanced NSCLC. Some background Standard therapy for NSCLC involves chemotherapy and radiation. Patients with advanced NSCLC may not respond to...
Read MoreSecond-line therapy for lung cancer – which is most effective?
In a nutshell This study investigated second-line treatments for non-small cell lung cancer (NSCLC). They found that second-line options are effective in advanced NSCLC. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Many cases of NSCLC are diagnosed at an advanced stage. First-line treatment...
Read MoreIs pembrolizumab effective as a first-line treatment in lung cancer?
In a nutshell This study investigated the effect of pembrolizumab (Keytruda) in non-small cell lung cancer (NSCLC). They found that this treatment was effective as a first-line therapy for NSCLC. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Patients with advanced NSCLC are usually treated...
Read MoreSBRT vs. radiotherapy in patients with inoperable non-small cell lung cancer
In a nutshell This study determined whether stereotactic body radiation therapy (SBRT) was more effective than standard radiotherapy in patients with inoperable non-small cell lung cancer. The study found that SBRT led to better survival outcomes for these patients, with minimal side effects. Some background Tumor removal by surgery is the standard of...
Read MoreSBRT vs. radiotherapy in patients with inoperable non-small cell lung cancer
In a nutshell This study determined whether stereotactic body radiation therapy (SBRT) was more effective than standard radiotherapy in patients with inoperable non-small cell lung cancer. The study found that SBRT led to better survival outcomes for these patients, with minimal side effects. Some background Tumor removal by surgery is the standard of...
Read MoreEffects on survival: thermal ablation vs stereotactic radiation therapy for non-small cell lung cancer
In a nutshell This article investigated the safety and effectiveness of thermal ablation (TA) compared to stereotactic radiation therapy (SRT) for the treatment of non-small-cell lung cancer (NSCLC). The authors concluded that both thermal ablation and stereotactic radiation are safe and can improve survival of these patients. Some...
Read MoreNivolumab compared to docetaxel in lung cancer that has been treated
In a nutshell This study wanted to find out if treating lung cancer with nivolumab (Opdivo) is better than treating it with docetaxel (Taxotere), specifically for lung cancer than has already been treated before. The study found that nivolumab worked better and was safer than docetaxel in treating lung cancer. Some background Nivolumab and docetaxel...
Read MoreBrigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
In a nutshell This study wanted to find out if the medication brigatinib (Alunbrig) is better than crizotinib (Xalkori) in treating patients with lung cancer. The study found that survival was significantly longer in patients who were treated with brigatinib compared to those treated with crizotinib. Some background Brigatinib and crizotinib are a...
Read MoreAlectinib vs crizotinib in treating brain or spinal cord tumors in patients with non-small cell lung cancer
In a nutshell This study wanted to find out which medication is better for treating lung cancer that has spread to the brain or spinal cord, crizotinib (Xalkori) or alectinib (Alecensa). The study found that alectinib worked better than crizotinib for treatment of tumors of the brain and spinal cord. Some background Alectinib and crizotinib are two...
Read More
